We are live on ! Find out more

FPRX

Five Prime Therapeutics, Inc.

FPRX

Delisted

FPRX was delisted on the 15th of April, 2021.

126 hedge funds and large institutions have $1B invested in Five Prime Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 42 reducing their positions, and 12 closing their positions.

New

Increased

Maintained

Reduced

Closed

42% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 12

36% more capital invested

Capital invested by funds: $737M → $1B (+$264M)

2% more funds holding

Funds holding: 123 → 126 (+3)

12% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 42

12% less call options, than puts

Call options by funds: $6.62M | Put options by funds: $7.52M

Holders

126

Holders Change

Holders Change %

+2.44%

% of All Funds

3.14%

Holding in Top 10

–

Holding in Top 10 Change

–

Holding in Top 10 Change %

–

% of All Funds

–

New

Increased

Reduced

Closed

Calls

$6.62M

Puts

$7.52M

Net Calls

-$898K

Net Calls Change

+$130K

Top Buyers

Rank	Fund	Capital Flow
1	HM HealthCor Management New York	+$31.7M
2	PAMU Pictet Asset Management (UK) London, United Kingdom	+$4.99M
3	Millennium Management New York	+$4.38M
4	Axa Paris, France	+$4.18M
5	Vanguard Group Malvern, Pennsylvania	+$2.79M

Top Sellers

Rank	Fund	Capital Flow
1	Renaissance Technologies New York	-$11.3M
2	State Street Boston, Massachusetts	-$10.9M
3	MWNA Marshall Wace North America New York	-$8.6M
4	Deutsche Bank Frankfurt Am Main Ge, Germany	-$6.61M
5	Goldman Sachs New York	-$4.52M

#	Name	Holding	Trade Value	Shares Change	Change in Stake
26	26 UBS AM Chicago, Illinois	$4.41M	+$176K	+5,600	+5%
27	27 Lord, Abbett & Co Jersey City, New Jersey	$4.18M	+$1.39M	+44,260	+76%
28	AIC 28 AWM Investment Company New York	$4.09M	–	–	–
29	29 DekaBank Deutsche Girozentrale Frankfurt, Germany	$3.72M	–	–	–
30	CS 30 Credit Suisse Zurich, Switzerland	$3.57M	-$64.2K	-2,044	-2%
31	IBT 31 International Biotechnology Trust London, United Kingdom	$3.54M	+$1.43M	+45,500	+111%
32	TCIM 32 TIAA CREF Investment Management New York	$3.03M	-$401K	-12,768	-15%
33	33 Renaissance Technologies New York	$2.89M	-$11.3M	-360,800	-84%
34	NFA 34 Nationwide Fund Advisors Columbus, Ohio	$2.87M	+$132K	+4,208	+6%
35	GC 35 Guggenheim Capital Chicago, Illinois	$2.81M	-$31.6K	-1,007	-1%
36	MWNA 36 Marshall Wace North America New York	$2.77M	-$8.6M	-273,812	-80%
37	TAM 37 Trillium Asset Management Boston, Massachusetts	$2.65M	-$12.5K	-399	-0.6%
38	38 Point72 Asset Management Stamford, Connecticut	$2.58M	+$1.98M	+62,982	New
39	39 Goldman Sachs New York	$2.56M	-$4.52M	-144,108	-70%
40	40 Morgan Stanley New York	$2.18M	-$2.62M	-83,509	-61%
41	CM 41 Crestline Management Fort Worth, Texas	$2.08M	+$1.6M	+50,919	New
42	AC 42 Ascend Capital Orinda, California	$2.07M	+$1.59M	+50,630	New
43	AG 43 Artal Group Luxembourg	$2.05M	-$3.14M	-100,000	-67%
44	CS 44 Candriam SCA Strassen, Luxembourg, Luxembourg	$2.05M	-$283K	-9,000	-15%
45	GPCM 45 Granite Point Capital Management Boston, Massachusetts	$2.05M	+$628K	+20,000	+67%
46	46 Swiss National Bank Zurich, Switzerland	$1.97M	–	–	–
47	47 Los Angeles Capital Management Los Angeles, California	$1.97M	-$158K	-5,040	-9%
48	48 AllianceBernstein Nashville, Tennessee	$1.89M	–	–	–
49	49 California State Teachers Retirement System (CalSTRS) West Sacramento, California	$1.79M	-$142K	-4,511	-9%
50	VIA 50 Vident Investment Advisory Alpharetta, Georgia	$1.67M	-$1.47M	-46,836	-53%

FPRX Hedge Fund Activity: Q3 2017 in Review

126 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q3 2017, worth a combined $1B — up 36% from $737M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new FPRX positions and 12 closed out — a net gain of 5 holders — while 37 added to existing stakes and 42 trimmed.

The largest buyer was HealthCor Management, opening a new position worth an estimated $31.7M. The largest seller was Renaissance Technologies, cutting an estimated $11.3M.

126 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q3 2017, up from 123 in Q2 2017.
Funds reported $1B of Five Prime Therapeutics, Inc. stock for Q3 2017, up 36% quarter-over-quarter.
17 funds opened new Five Prime Therapeutics, Inc. positions in Q3 2017 and 12 closed out, a net change of +5 holders.
The largest Five Prime Therapeutics, Inc. buyer in Q3 2017 was HealthCor Management, an estimated $31.7M added.
The largest Five Prime Therapeutics, Inc. seller in Q3 2017 was Renaissance Technologies, an estimated $11.3M sold.

Based on aggregated 13F filings for Q3 2017.

Five Prime Therapeutics, Inc. FPRX